[A20-77] Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2020
Project no.:
A20-77
Commission:
Commission awarded on 28.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Indication:
Patients with cystic fibrosis aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene |
Result of dossier assessment:
Added benefit not proven due to a lack of suitable study data |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2021.02.18 A G-BA decision was published.